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Breast Cancer Risk for Female Relatives of Male Breast Cancer Patients
with Negative BRCA1/2 Testing
Emily Martin, BS
Advisory Professor: Chelsea Wagner, MS, CGC
Abstract
Risk models exist to estimate a female’s lifetime risk of breast cancer in the absence of a
hereditary predisposition to cancer, namely Hereditary Breast and Ovarian Cancer syndrome. These risk
models consider various factors such as reproductive history and family history, but few models take a
family history of male breast cancer into account. This study aims to evaluate if prevalence of breast
cancer among female relatives is higher when there is a family history of male breast cancer in the
context of uninformative BRCA1 and BRCA2 testing. This information may aid in the process of risk
assessments for patients and their families following uninformative germline genetic testing.
A retrospective chart review was performed to compare the family histories of males with
breast cancer (the case group) and males with prostate cancer (the comparison group) following
uninformative BRCA1 and BRCA2 germline genetic testing. Univariate logistic regression was performed
to calculate odds ratios for first- and second-degree relatives with statistical significance assumed at p <
0.05.
Our data showed a statistically significant difference in odds ratio for first-degree relatives,
however the comparison group may have had a selection bias. There was no statistically significant
difference in odds ratios for maternal and paternal second-degree relatives. These results support
current clinical recommendations for female relatives of male breast cancer patients following
uninformative BRCA1 and BRCA2 testing, however further research is needed to better characterize the
risk to female family members of males with breast cancer.
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Illustrations
Figure 1: Flowchart depicting the process by which the case and comparison groups were selected from
MD Anderson clinical cancer genetics database.
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Table 1: Demographic Information and Cancer History for the Case and Comparison Groups
Case (N = 134)
Comparison (N = 134)
P Value
N
%
N
%
Mean Current Age/Age
67.48
68.08
0.64
at Death (Years)
Ethnicity/Race
0.91
White/Not Hispanic or Latino
107
79.85%
107
79.95%
Black/African American
13
9.70%
13
9.70%
Hispanic/Latino
10
7.46%
12
8.96%
Asian
3
2.24%
1
0.75%
Other
1
0.75%
1
0.75%
Cancer History
Mean Age of Dx (Years)
59.24
61.05
0.29
Multiple Primary Cancer
33
24.63%
1
0.75%
< 0.01
Mean # of Primary Cancers
1.52
1
Dx, diagnosis
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Case
Comparison
P Value
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%
N
%
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3.49
0.21
Positive Family History of BC
35
26.12%
49
36.57%
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Mean # of Relatives with BC
1.06
1.22
Mean Age of Dx of BC (Years)
59.08
56.53
0.32
No Family History Available
4
2.99%
Mean # of Relatives
2.75
2.50
0.22
Positive Family History of BC
21
15.67%
13
9.70%
0.08
Mean # of Relatives with BC
1.24
1.38
Mean Age of Dx of BC (Years)
61.62
53.63
0.06
No Family History Available
12
8.96%
Mean # of Relatives
2.83
2.63
0.08
Positive Family History of BC
21
16.80%
13
9.70%
0.10
Mean # of Relatives with BC
1.05
1.08
Mean Age of Dx of BC (Years)
57.63
57.27
0.73
No Family History Available
9
6.72%
BC, breast cancer; Dx, diagnosis; FDRs, first-degree relatives; pSDRs, paternal second-degree relatives; mSDRs, maternal seconddegree relatives
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1.0 Introduction
Breast cancer is the leading non-skin cancer diagnosed among females, and the second leading
cause of cancer death.1 It is estimated that a female’s lifetime risk for developing breast cancer is
currently 12.9%.2 Males are less frequently affected with an estimated lifetime risk for developing
breast cancer of 0.1%.3
Several risk factors contribute to an individual’s risk of developing breast cancer. For males,
hormonal imbalances and radiation exposure incurred in the treatment of prostate cancer and
lymphoma have been linked to an increased risk of developing male breast cancer.4,5 A female’s
reproductive history, hormonal medications, and lifestyle factors contribute to her lifetime risk.1,6,7
While most breast cancer cases are considered sporadic, about 5-10% of all breast cancers develop due
to a pathogenic variant in BRCA1 or BRCA2, associated with Hereditary Breast and Ovarian Cancer
syndrome (HBOC). 8 Males with HBOC have up to a 7% lifetime risk of developing breast cancer.4
Currently, any male diagnosed with breast cancer meets the National Comprehensive Cancer Network’s
(NCCN) guidelines for BRCA1 and BRCA2 germline genetic testing.9
In the absence of a known hereditary predisposition, about 20% of breast cancer cases are
familial. 8 A positive family history of breast cancer is a risk factor for both male and female breast
cancer.4,5,6,10 Previous studies have shown that a positive family history of female breast cancer incurs a
relative risk of 1.76 for male breast cancer when there is one affected first degree relative, and 2.28
when there are two affected first degree relatives.11 Conversely, these studies have reported a relative
risk of 1.90 for female breast cancer when there is one affected first degree relative with male breast
cancer, but these studies do not rule out a hereditary predisposition to breast cancer.11
Awareness of an individual’s pertinent risk factors can aid in making tailored cancer screening
recommendations in the absence of an identifiable hereditary predisposition to cancer. Risk models
such as the Gail model and Tyrer-Cuzick Model estimate a female’s lifetime risk of breast cancer in the
absence of HBOC. 7,12 These types of models consider factors such as personal reproductive history or
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family history of breast cancer among females, but few models take a family history of male breast
cancer into account as sufficient data on the risk is not yet available. There is limited data for breast
cancer risk for female relatives of males with breast cancer in the absence of HBOC.
This study aims to evaluate the prevalence of female breast cancer when there is a family
history of male breast cancer in the setting of uninformative BRCA1 and BRCA2 germline genetic
testing. This information may aid in the process of risk assessments for patients and their families
following uninformative germline genetic testing.

2.0 Methods
This study was approved by the Institutional Review Board at The University of Texas MD
Anderson Cancer Center (2020-0543) and The University of Texas Health Science Center at Houston
(HSC-DB-20-0869). A waiver of informed consent was approved by the institutional review board.
2.1 Subjects
This study is a retrospective chart review involving a case group and a comparison group. Study
participants in the case group included adult males with a diagnosis of breast cancer who completed a
genetic counseling consultation and germline genetic testing at MD Anderson Cancer Center in
Houston, Texas between May 1, 1994 to June 30, 2020 and who had uninformative BRCA1 and BRCA2
germline genetic testing (defined as a negative result or a result with a variant of uncertain significance
[VUS]). Males were excluded if they were found to have a pathogenic variant in a gene related to
hereditary breast cancer, if there was a reported family history of a pathogenic variant in a gene related
to hereditary breast cancer, or if they had a history of lymphoma or prostate cancer prior to their
diagnosis of breast cancer.
The comparison group included males with a diagnosis of prostate cancer who met the same
inclusion criteria as the case group. Subjects were excluded if there was a pathogenic variant in a gene
related to hereditary breast cancer, if there was a reported family history of a pathogenic variant in a
2

gene related to hereditary breast cancer, if they had a personal history of breast cancer, or if there was
an incomplete family history in their medical record. Of note, males who present to MD Anderson
Cancer Center with metastatic prostate cancer receive either pre-test counseling via a pre-recorded
video or a full in-person genetic counseling session if their family histories warrant a more extensive
risk assessment.
2.2 Data Collection
Data was extracted from MD Anderson’s Clinical Cancer Genetics database between September
1, 2020 and December 31, 2020.
Data was de-identified and stored in a Microsoft Excel file on a secure cloud-based drive. For
males with breast cancer, the age at breast cancer diagnosis, pathology of the breast cancer
(categorized as invasive ductal carcinoma, ductal carcinoma in situ, invasive ductal carcinoma with a
ductal carcinoma in situ component, or other), and hormone receptor status was recorded. For males
with prostate cancer, information about whether the prostate cancer was metastatic or had a Gleason
score of ≥ 7 was recorded. The following data points were collected for all subjects: age; ethnicity/race
(categorized as White/Not Hispanic or Latino, Black/African American, Hispanic/Latino, Asian, or Other);
any known Ashkenazi Jewish ancestry; any additional cancer diagnoses including cancer type; the
genetic test performed (categorized as panel testing or BRCA1 and BRCA2 testing), and for panel
testing, the type of panel ordered (categorized as an indication-based panel or expanded multi-gene
panel); the result of the genetic test (categorized as negative or VUS); the total number of female firstdegree relatives age ≥ 30 years at the time of data collection, and of those, the number with a diagnosis
of breast cancer; the total number of female maternal and paternal second-degree relatives age ≥ 30
years at the time of data collection, and of those, the number with a diagnosis of breast cancer; and the
ages of breast cancer diagnosis for all first- and second-degree relatives. If a subject had an incomplete
family history, it was noted and the family history that was available was collected.
2.3 Data Analysis
3

Case subjects were matched with a comparison subject using the R programming language in a
1:1 ratio based on ethnicity/race, current age, and family size (defined as the total number of first- and
second-degree female relatives age ≥ 30 years). If a case subject did not have a complete family history
available, family size was not considered as part of the matching process and they were matched to a
comparison subject based on ethnicity/race and current age only. An excess of comparison subjects
were included in data collection to facilitate more accurate matching between the two groups.
Data was analyzed with STATA (version 13.1) and R (version 3.6.3) programming software and
statistical significance was assumed at p < 0.05. Means and frequencies were reported for
demographic information for the case and comparison groups. χ2 and Fisher’s exact analyses were used
to compare categorical variables and Wilcoxon rank sum tests were used to compare numerical and
continuous variables between case and comparison subjects where p-values were estimated.
Univariate logistic regression adjusted for the covariates of current age, ethnicity/race, and family size
was performed with case/comparison status as the response variable, and prevalence of breast cancer
among female relatives age ≥ 30 years as the predictor. First-degree relatives, paternal second-degree
relatives, and maternal second-degree relatives were analyzed both independently and together using
this method. These analyses produced odds ratios (ORs) with a corresponding 95% confidence interval
(CI). Pooled prevalence of breast cancer among female relatives age ≥ 30 years was calculated by
averaging the number of affected females across all subjects and dividing by the total number of female
relatives across all subjects. This was done to reduce skewed values among families with a positive
family history of breast cancer.

4

3.0 Results
In total, data was collected on 134 men with breast cancer and 200 men with prostate cancer.
After matching, 278 participants were included in data analysis: 134 men with breast cancer and 134
men with prostate cancer (Figure 1).

Figure 1: Flowchart depicting the process by which the case and comparison groups were selected from
MD Anderson clinical cancer genetics database.
3.1 Demographics
Demographic information for the case and comparison groups is summarized in Table 1.
There were no significant differences between the case and comparison groups by current age at the
time of data collection, race/ethnicity, and age of cancer diagnosis (p = 0.64, p = 0.91, p = 0.29,
respectively). There was a significant difference between the number of subjects with multiple
primaries between the case and comparison groups (p < 0.01), with 24.63% the males in the case group
reporting multiple primaries and 0.75% of males in the comparison group reporting multiple primaries.
Among males in the case group who reported multiple primary cancers, 9.10% (3/33) reported two
breast primaries.

5

Table 1: Demographic Information and Cancer History for the Case and Comparison Groups
Case (N = 134)
Comparison (N = 134)
P Value
N
%
N
%
Mean Current Age/Age
67.48
68.08
0.64
at Death (Years)
Ethnicity/Race
0.91
White/Not Hispanic or Latino
107
79.85%
107
79.95%
Black/African American
13
9.70%
13
9.70%
Hispanic/Latino
10
7.46%
12
8.96%
Asian
3
2.24%
1
0.75%
Other
1
0.75%
1
0.75%
Cancer History
Mean Age of Dx (Years)
59.24
61.05
0.29
Multiple Primary Cancer
33
24.63%
1
0.75%
< 0.01
Mean # of Primary Cancers
1.52
1
Dx, diagnosis

3.2 Cancer Pathology
For subjects diagnosed with breast cancer, 77.61% (104/134) of tumors were described as
invasive ductal carcinoma, 8.21% (11/134) of tumors were described as invasive ductal carcinoma with
a ductal carcinoma in situ component, 6.72% (9/134) were described as ductal carcinoma in situ, and
7.46% (10/134) of tumors were described as an other tumor type. These included invasive lobular
carcinoma, mucinous tumors, papillary tumors, and tumors with unknown pathology. 90.30% (121/134)
of tumors were ER/PR positive, 4.48% (6/134) of tumors were ER/PR negative, and 5.22% (7/134) of
tumors did not report on ER/PR receptor status. 78.36% (105/134) of tumors were HER-2 negative,
3.73% (5/134) of tumors were HER-2 positive, 4.48% (6/134) of tumors were HER-2 equivocal, and
13.43% (18/134) of tumors did not report on HER-2 receptor status.
For the comparison group, 94.03% (126/134) of subjects had a prostate cancer diagnosis that
was considered metastatic or had a Gleason score ≥ 7. 5.97% (8/134) of subjects had a prostate cancer
diagnosis that was considered non-metastatic or with a Gleason score of < 7.
3.3 Genetic Testing
62.69% (84/134) of case subjects received BRCA1 and BRCA2 germline genetic testing and
37.31% (50/134) of case subjects received panel genetic testing which included BRCA1 and BRCA2. For
6

case subjects who underwent panel testing, a hereditary breast cancer panel was the most commonly
ordered test. While the genes included on hereditary breast cancer panels varied by lab and ordering
provider, these panels generally analyzed well-established genes associated with hereditary breast
cancer. 5.22% (7/134) of comparison subjects received BRCA1 and BRCA2 genetic testing only and
94.78% (127/134) of comparison subjects received panel genetic testing which included BRCA1 and
BRCA2. For comparison subjects who underwent panel testing, a hereditary prostate cancer panel was
the most commonly ordered test. Similar to the hereditary breast cancer panel, these panels varied by
lab and ordering provider, but included well-established genes associated with hereditary prostate
cancer. There was a statistically significant difference for the type of genetic testing performed
between the case group and comparison group (p < 0.001).
90.30% (121/134) of case subjects received a negative genetic test result and 9.70% (13/134) of
case subjects were found to have at least one VUS. Comparatively, 88.81% (119/134) of comparison
subjects received a negative genetic test result and 11.19% (15/134) of comparison subjects were
found to have at least one VUS. There was no statistically significant difference for genetic test results
between the case and comparison groups (p = 0.69).
3.4 Family History
Family history data for first- and second-degree female relatives is summarized in Table 2.
There was no statistically significant difference between case and comparison groups for total number
of female first degree relatives (FDRs) age ≥ 30 years (p = 0.21) or for total number of female FDRs age
≥ 30 years with breast cancer (p = 0.06). Using univariate logistic regression, an OR for the case group
was 0.62 (95% CI 0.40-0.95) based on family history of breast cancer among female FDRs age ≥ 30
years. There was no statistically significant difference between ORs when calculated for each reported
ethnicity/race. Of note, one comparison subject reported a male FDR with a history of breast cancer,
but this diagnosis was not included in data analysis.
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There was no statistically significant difference between case and comparison groups for the
total number of female paternal second-degree relatives (pSDR) age ≥ 30 years (p = 0.22) or female
pSDRs age ≥ 30 years with breast cancer (p = 0.08). There was no statistically significant difference
between case and comparison groups for the total number of female maternal second-degree relatives
(mSDR) age ≥ 30 years (p = 0.08) or female mSDRs age ≥ 30 years with breast cancer (p = 0.10). The ORs
for pSDRs and mSDRs among the case group was not statistically significant. The OR for pSDRs was
calculated to be 0.74 (95% CI 0.13-4.20) and the OR for mSDRs was calculated to be 1.00 (95% CI 0.195.34). There was no statistically significant difference between ORs when calculated for each reported
ethnicity/race.
An OR was calculated for total family size by combining FDR, pSDR, and mSDR family histories
and adjusting for the covariates of age, race/ethnicity, and family size. This value was not found to be
statistically significant at 1.01 (95% CI 0.17-5.80).
The pooled prevalence of breast cancer among female FDRs and SDRs age ≥ 30 years is
summarized in Table 3. There was no statistically significant difference in pooled prevalence of breast
cancer between the case and comparison groups.
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Table 2: Family History of Female Breast Cancer Among First- and Second-Degree Relatives Age ≥ 30
Years for Case and Comparison Groups
Case
Comparison
P Value
(N = 134)
(N = 134)
N
%
N
%
Mean # of Relatives
3.15
3.49
0.21
Positive Family History of BC
35
26.12%
49
36.57%
0.06
Mean # of Relatives with BC
1.06
1.22
Mean Age of Dx of BC (Years)
59.08
56.53
0.32
No Family History Available
4
2.99%
Mean # of Relatives
2.75
2.50
0.22
Positive Family History of BC
21
15.67%
13
9.70%
0.08
Mean # of Relatives with BC
1.24
1.38
Mean Age of Dx of BC (Years)
61.62
53.63
0.06
No Family History Available
12
8.96%
Mean # of Relatives
2.83
2.63
0.08
Positive Family History of BC
21
16.80%
13
9.70%
0.10
Mean # of Relatives with BC
1.05
1.08
Mean Age of Dx of BC (Years)
57.63
57.27
0.73
No Family History Available
9
6.72%
BC, breast cancer; Dx, diagnosis; FDRs, first-degree relatives; pSDRs, paternal second-degree relatives; mSDRs, maternal seconddegree relatives

Table 3: Pooled Prevalence of Female Breast Cancer Among First- and Second-Degree Relatives
Between the Case and Comparison Groups
Case (N = 134)
Comparison (N = 134)
P Value
FDRs
9.02%
12.82%
0.09
pSDRs
7.74%
5.37%
0.28
mSDRs
6.17%
3.98%
0.24
FDRs, first-degree relatives; pSDRs, paternal second-degree relatives; mSDRs, maternal second-degree relatives

4.0 Discussion
The results of our study suggest that there is no significant difference in the family histories of
breast cancer among female relatives age ≥ 30 years when comparing subjects with male breast cancer
(case) to subjects with prostate cancer (comparison) in the context of uninformative BRCA1 and BRCA2
germline genetic testing. Previous research has demonstrated that male breast cancer is associated
with an increased risk of breast cancer for unaffected female relatives, but limited data exists to
characterize the risk to unaffected female relatives in the absence of a hereditary predisposition to
breast cancer, namely HBOC.4,10,11 Our data suggests that in the absence of a hereditary predisposition
to breast cancer, a family history of male breast cancer may not impact a female relative’s risk.
9

The comparison groups suggest that they are similar in age (p = 0.64), reported ethnicity/race
(p = 0.91), and family size (FDRs p = 0.21; pSDRs p = 0.22; mSDRs p = 0.08). This implies that matching
between the two groups produced a uniform cohort when accounting for the covariates of age,
reported ethnicity/race, and family size, and this reduces differences of several variables that
contribute towards a female relative’s breast cancer risk.6,13
The mean age of diagnosis of male breast cancer was 59.24 years which is younger than the
median age of diagnosis of 67 years that has been previously reported.14,15 Males with breast cancer
were more likely to have multiple primaries compared to the comparison group (p < 0.01). Outside of
prostate cancer and lymphoma, cancer history was not selected against for the case group. The high
proportion of males with breast cancer who reported additional cancer primaries suggests either that
additional cancer history could be a risk factor to develop male breast cancer or that a history of male
breast cancer could incur a risk to develop subsequent cancers later in life. This was not the focus of
our study but could be an area of interest for future research. A large proportion of male breast cancer
tumors were IDC, hormone receptor positive, and HER-2 negative, consistent with tumor demographics
previously reported in the literature.14,15
There was a significant difference between the type of genetic testing ordered for the case and
comparison groups, with males with a diagnosis of breast cancer more likely to have undergone BRCA1
and BRCA2 testing only vs. panel testing (p < 0.001). This difference can be attributed to several factors,
including data available on hereditary predispositions to male breast cancer compared to male prostate
cancer. BRCA1 and BRCA2 were the first genes to be associated with an increased risk of male breast
cancer.15 Since then, other genes such as CHEK2 and PALB2 have been associated with male breast
cancer, but their risks are still not well quantified.4,15,16 Similarly, BRCA1 and BRCA2 were identified as
genes associated with an increased risk of prostate cancer. Additional genes including those associated
with Lynch syndrome, ATM, and PALB2 have been associated with prostate cancer, and these risks are
now well-established. 17,18 Updates to the NCCN guidelines reflect the expansion of knowledge about
10

hereditary prostate cancer coming out of more recent publications, whereas male breast cancer has
been included in these guidelines for much longer.
VUS rates were similar between the case and comparison groups, despite the difference in
rates of panel testing. Most panels selected only included well-established genes relevant to the
patient’s personal and family history, thereby resulting in lower VUS rates when compared to larger
panels.
When evaluating family histories, our study shows no significant difference between the family
histories of breast cancer among FDRs, SDRs, or pooled prevalence for the case and comparison groups.
Our data shows a higher prevalence of breast cancer among FDRs in the comparison group and a higher
prevalence of breast cancer among SDRs in the case group. None of these differences are statistically
significant, although the difference between FDRs trended towards significance with a p-value of <
0.10, highlighting the need for larger studies. These differences in family history could be due in part to
a selection bias in the comparison group.
Males with prostate cancer who received pre-test genetic counseling from a genetic counselor
were more likely to have a complete family history in the cancer genetics database compared to males
who received pre-test counseling by video. Because a complete family history was required in order to
be included in the comparison group, it is possible that males who received a full genetic counseling
session and therefore had more extensive family histories of cancer were more likely to be selected for
the comparison group.
The pooled prevalence of breast cancer among female FDRs age ≥ 30 years was greater than
the prevalence of breast cancer among female SDRs age ≥ 30 years. Previous research has shown that
individuals are more likely to report a positive family history among FDRs than among SDRs.19
Interestingly, previous research has also demonstrated that paternal family history is underreported
when compared to maternal family history.19 Underreporting of paternal family history was not seen in
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our data, which may be attributed to our study only analyzing data when there was a complete
paternal family history reported.
Using the Surveillance, Epidemiology, and End Results (SEER) Cancer Query System, the
estimated complete prevalence of breast cancer among females age ≥ 30 years is 3.50%.2 This number
does not reflect females who were diagnosed and subsequently died and therefore is likely a
conservative estimate. Along with a female’s lifetime risk of 12.9% to develop breast cancer, we can use
these two estimates as a range to interpret the prevalence of female breast cancer among female
relatives age ≥ 30 years in our data. 2 All pooled prevalence values were between 3.50% and 12.9%
which falls within the range of prevalence values from the SEER data. This suggests a nonsignificant
result and that our comparison group may have similar breast cancer rates to the general population.
4.1 Missing Data
Pedigrees documented in the medical record represent family histories of cancer at that
moment in time, rather than family histories that are regularly updated. Because of this, it is possible
that family members in the case or comparison groups could have developed breast cancer at a later
time and these diagnoses were not included in data analysis. Having updated family history could alter
the ORs as well as the pooled prevalence values for our data. Further, not all males in the case group
had complete family histories on file, either because they were not reported or because they were
unknown to the patient. This limits the amount of family history information available in data analysis.
4.2 Limitations
The comparison group was selected because it was necessary to compare our case subjects to a
cohort who presented for genetic counseling, had a complete pedigree in the medical record, and had
undergone BRCA1 and BRCA2 germline genetic testing. However, we acknowledge that males in the
comparison group also have a personal history of cancer and this could impact familial cancer risks and
thus skew the results of our data analysis. There are reports of associations between familial breast
cancer and familial prostate cancer, but these studies do not rule out HBOC for participants.20 To our
12

knowledge, no association between prostate cancer and female breast cancer in the absence of HBOC
has been reported in the literature.
Additionally, there are pathogenic variants in genes besides BRCA1 and BRCA2 that have been
shown to contribute to breast cancer risk in males and females.4,5,6,13 As we learn more about the
impact of other genes on male and female breast cancer risk, future studies will be needed to
determine how negative genetic testing in a proband influences familial breast cancer risk.
Lastly, individuals in our study are those undergoing active treatment for a medical condition,
those motivated to pursue genetic testing for familial implications, or those who report family history
to a provider that resulted in a genetics referral. All of these factors can contribute to a patient that is
more likely to report a positive family history related to their medical concern.21,22,23

5.0 Conclusion
In this study, there was no statistically significant difference in family history of female breast
cancer between the case and comparison group, and both groups reported family histories of breast
cancer that were within the range of the SEER database’s prevalence estimates.
These results support current clinical breast screening recommendations for female family
members of male breast cancer patients with uninformative BRCA1 and BRCA2 germline genetic
testing, which include breast screening based on personal risk factors and family histories of female
breast cancer. Future research evaluating how family histories of unaffected comparison subjects who
have uninformative BRCA1 and BRCA2 germline genetic testing are now needed to confirm the findings
of our study. Studies investigating how family history of cancer influences an individual’s risk of cancer,
like this one, have the potential to improve personalized risk assessment and better identify patients
that may benefit from enhanced screening.
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